Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rostand, S. G.
Right arrow Articles by Victor, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rostand, S. G.
Right arrow Articles by Victor, R. G.

Journal of the American Society of Nephrology, Vol 2, 1053-1062, Copyright © 1991 by American Society of Nephrology


EDITORIALS

Cardiovascular complications in renal failure

SG Rostand, JD Brunzell, RO Cannon 3d and RG Victor

Cardiovascular diseases are a leading cause of death in end-stage renal disease (ESRD) largely as a result of the progressively increasing age of ESRD patients and the broad constellation of uremia-associated factors that can adversely affect cardiac function. Hypertension, one of the leading causes of renal failure, is a major culprit in this process, causing left ventricular hypertrophy, cardiac chamber dilation, increased left ventricular wall stress, redistribution of coronary blood flow, reduced coronary artery vasodilator reserve, ischemia, myocardial fibrosis, heart failure, and arrhythmias. In addition to impairing the coronary microcirculation, hypertension may contribute to the development of atherosclerotic coronary artery disease, particularly in the presence of the many lipid abnormalities observed in ESRD. These patients have reduced high-density lipoprotein cholesterol and increased plasma triglyceride concentrations, and there is a defect in cholesterol transport. Other abnormalities that may contribute to atherosclerotic coronary artery disease in ESRD are reduced high-density lipoprotein cholesterol synthesis and reduced activity of the reverse cholesterol pathway. Treatment with fibric acids, nicotinic acids, and lovastatin may be useful in lowering cholesterol and triglyceride concentrations in some of these patients. The incidence of coronary artery disease in ESRD populations is difficult to determine. About 25 to 30% of ESRD patients with angina have no evidence of significant coronary artery disease, and an undetermined number have silent coronary disease. The presence of resting electrocardiographic abnormalities caused by hypertension or conduction defects makes it difficult to accurately diagnosis coronary artery disease in ESRD populations by noninvasive methods, including exercise testing and thallium scintigraphy with or without the use of dipyridamole. Hypotension is a frequent complication of the dialytic process. Many factors have been implicated, including autonomic neuropathy. There is no consensus on the function of the efferent limb of the sympathetic nervous system. The afferent limb (arterial baroreflex function) is felt to be impaired. Further, there may be defects in the ability of the cardiovascular system to respond to sympathetic nerve activity. Most studies of autonomic function have used indirect measurements. Studies are underway that use techniques to assess sympathetic function directly. Such experiments with microneuropathy suggest greater skeletal sympathetic muscle discharge in uremic patients than in normal patients.


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
T. Hayashi, Y. Obi, T. Kimura, K.-i. Iio, S. Sumitsuji, Y. Takeda, Y. Nagai, and E. Imai
Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2936 - 2942.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. Genovesi, O. Bracchi, P. Fabbrini, E. Luisetto, M. R. Vigano, D. Lucini, M. Malacarne, A. Stella, and M. Pagani
Differences in heart rate variability during haemodialysis and haemofiltration
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2256 - 2262.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. Tatematsu, S. Wakino, T. Kanda, K. Homma, K. Yoshioka, K. Hasegawa, N. Sugano, M. Kimoto, T. Saruta, and K. Hayashi
Role of Nitric Oxide-Producing and -Degrading Pathways in Coronary Endothelial Dysfunction in Chronic Kidney Disease
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 741 - 749.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. Dikow, L. P. Kihm, M. Zeier, J. Kapitza, J. Tornig, K. Amann, C. Tiefenbacher, and E. Ritz
Increased Infarct Size in Uremic Rats: Reduced Ischemia Tolerance?
J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1530 - 1536.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. M. Sadeghi, G. W. Stone, C. L. Grines, R. Mehran, S. R. Dixon, A. J. Lansky, M. Fahy, D. A. Cox, E. Garcia, J. E. Tcheng, et al.
Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction
Circulation, December 2, 2003; 108(22): 2769 - 2775.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. Hocher, R. Ziebig, C. Altermann, R. Krause, G. Asmus, C.-M. Richter, T. Slowinski, P. Sinha, and H.-H. Neumayer
Different Impact of Biomarkers as Mortality Predictors among Diabetic and Nondiabetic Patients Undergoing Hemodialysis
J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2329 - 2337.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G. P. Bezante, G. Deferrari, et al.
Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension
Hypertension, July 1, 2003; 42(1): 14 - 18.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Hausberg, M. Kosch, P. Harmelink, M. Barenbrock, H. Hohage, K. Kisters, K. H. Dietl, and K. H. Rahn
Sympathetic Nerve Activity in End-Stage Renal Disease
Circulation, October 8, 2002; 106(15): 1974 - 1979.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
L. M. Ruilope, D. J. van Veldhuisen, E. Ritz, and T. F. Luscher
Renal function: the Cinderella of cardiovascular risk profile
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1782 - 1787.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. AMANN, G. MIL TENBERGER-MIL TENYI, A. SIMONOVICIENE, A. KOCH, S. ORTH, and E. RITZ
Remodeling of Resistance Arteries in Renal Failure: Effect of Endothelin Receptor Blockade
J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2040 - 2050.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. RUILOPE, A. SALVETTI, K. JAMERSON, L. HANSSON, I. WARNOLD, H. WEDEL, and A. ZANCHETTI
Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study
J. Am. Soc. Nephrol., February 1, 2001; 12(2): 218 - 225.
[Abstract] [Full Text]


Home page
Nephrol Dial TransplantHome page
K. Amann and E. Ritz
Microvascular disease--the Cinderella of uraemic heart disease
Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1493 - 1503.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. KIMURA, F. GEJYO, S. SUZUKI, and R. MIYAZAKI
The C677T Methylenetetrahydrofolate Reductase Gene Mutation in Hemodialysis Patients
J. Am. Soc. Nephrol., May 1, 2000; 11(5): 885 - 893.
[Abstract] [Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
L. Labrousse, C. de Vincentiis, F. Madonna, C. Deville, X. Roques, and E. Baudet
Early and long term results of coronary artery bypass grafts in patients with dialysis dependant renal failure
Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 691 - 696.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. J. Schmidt, S. Yokota, T. S. Tracy, M. I. Sorkin, and C. Baylis
Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis
Am J Physiol Renal Physiol, May 1, 1999; 276(5): F794 - F797.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. KIMURA, F. GEJYO, T. YAMAGUCHI, S. SUZUKI, T. IMURA, R. MIYAZAKI, and M. ARAKAWA
A Cholesteryl Ester Transfer Protein Gene Mutation and Vascular Disease in Dialysis Patients
J. Am. Soc. Nephrol., February 1, 1999; 10(2): 294 - 299.
[Abstract] [Full Text]


Home page
J. Am. Soc. Nephrol.Home page
J. TÖRNIG, M.-L. GROSS, A. SIMONAVICIENE, G. MALL, E. RITZ, and K. AMANN
Hypertrophy of Intramyocardial Arteriolar Smooth Muscle Cells in Experimental Renal Failure
J. Am. Soc. Nephrol., January 1, 1999; 10(1): 77 - 83.
[Abstract] [Full Text]


Home page
Arch Intern MedHome page
J. Mattana, C. Effiong, R. Gooneratne, and P. C. Singhal
Outcome of Stroke in Patients Undergoing Hemodialysis
Arch Intern Med, March 9, 1998; 158(5): 537 - 541.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Robinson, A. Gupta, V. Dennis, K. Arheart, D. Chaudhary, R. Green, P. Vigo, E. L. Mayer, J. Selhub, M. Kutner, et al.
Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine Concentrations
Circulation, December 1, 1996; 94(11): 2743 - 2748.
[Abstract] [Full Text]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP